Literature DB >> 2104910

Differential expression of the HLA class I multigene family by human embryonal carcinoma and choriocarcinoma cell lines.

T F Rinke de Wit1, S Vloemans, P J van den Elsen, A Haworth, P L Stern.   

Abstract

We have studied the expression of both HLA class and the recently described HLA class I-like genes (HLA-E and HLA-6.0) in two human developmental tumor cell lines, that serologically could not be typed for HLA-A, -B, and -C. Evidence is presented that the teratocarcinoma Tera-2 stem cells express trace amounts of non-beta 2 microglobulin-associated classical HLA-A, -B, and -C Ag on their cell surface. The Jeg-3 human choriocarcinoma cells derived from fetal trophoblast express normal levels of surface beta 2 microglobulin associated with 45-kDa and 41-kDa H chains that display unique isoelectric points in IEF gels. The HLA-6.0 or HLA-E genes may encode the lower molecular mass component on Jeg-3 cells, because these genes express molecules of about 38 kDa and 41 kDa, respectively, when transfected to appropriate host cells. Transcripts homologous to the HLA-6.0 gene are found to be constitutively expressed in the Jeg-3 cells but not in Tera-2 cells, whereas HLA-E is not significantly transcribed in either cell line. Transcription of class I (HLA-A, -B, and -C) and class I-like (HLA-E and HLA-6.0) genes is up-regulated after treatment with IFN-gamma in Tera-2 cells, whereas the corresponding genes in Jeg-3 cells remain essentially unresponsive. The biologic role of trophoblast class I(-like) molecules in the context of the maternal acceptance of the fetal semiallograft is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104910

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Intraepithelial lymphocytes in celiac disease immunopathology.

Authors:  Valérie Abadie; Valentina Discepolo; Bana Jabri
Journal:  Semin Immunopathol       Date:  2012-06-03       Impact factor: 9.623

2.  HLA class I homologous transcripts in the human embryonal carcinoma cell line Tera-2.

Authors:  T F Rinke de Wit; L Struyk; S Vloemans; J Glazebrook; J M Boyle; P L Stern; P J van den Elsen
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

3.  HLA-E is the only class I gene that escapes CpG methylation and is transcriptionally active in the trophoblast-derived human cell line JAR.

Authors:  J Boucraut; T Guillaudeux; M Alizadeh; J Boretto; G Chimini; F Malecaze; G Semana; R Fauchet; P Pontarotti; P Le Bouteiller
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

4.  Calreticulin associates with non-HLA-A,-B class I proteins in the human choriocarcinoma cell lines JEG-3 and BeWo.

Authors:  S D Wainwright; K L Simpson; C H Holmes
Journal:  Immunology       Date:  1998-03       Impact factor: 7.397

5.  Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts.

Authors:  L Crisa; M T McMaster; J K Ishii; S J Fisher; D R Salomon
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

6.  Reprogramming of CTLs into natural killer-like cells in celiac disease.

Authors:  Bertrand Meresse; Shane A Curran; Cezary Ciszewski; Gerasim Orbelyan; Mala Setty; Govind Bhagat; Leanne Lee; Maria Tretiakova; Carol Semrad; Emily Kistner; Robert J Winchester; Veronique Braud; Lewis L Lanier; Daniel E Geraghty; Peter H Green; Stefano Guandalini; Bana Jabri
Journal:  J Exp Med       Date:  2006-05-08       Impact factor: 14.307

Review 7.  T Cells in Celiac Disease.

Authors:  Bana Jabri; Ludvig M Sollid
Journal:  J Immunol       Date:  2017-04-15       Impact factor: 5.422

8.  Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11.

Authors:  D J Schust; D Tortorella; J Seebach; C Phan; H L Ploegh
Journal:  J Exp Med       Date:  1998-08-03       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.